FDA approves Eli Lilly’s Kisunla for Alzheimer’s treatment
The U.S. Food and Drug Administration (FDA) has approved Kisunla (donanemab-azbt), an Alzheimer’s treatment developed by Eli Lilly and Company (NYSE: LLY). This treatment, specifically designed for adults with early symptomatic Alzheimer’s disease, includes those with mild cognitive impairment (MCI) and the mild dementia stage of Alzheimer’s, with confirmed amyloid pathology. Priced at $350 million […]